Lisata Therapeutics - On Aug 3, Approved Reduction In Workforce By About 72% Effective Immediately - SEC Filing - LSTA News | RalliesLisata Therapeutics - On Aug 3, Approved Reduction In Workforce By About 72% Effective Immediately - SEC Filing
L
LSTA• Workforce reduction approved
- Lisata Therapeutics Inc. approved a reduction in workforce of about 72% effective immediately on Aug. 3, according to an SEC filing.
- The company estimates $1.20 million of costs related to the workforce reduction through the quarter ending Sept. 30, 2026.
- Lisata said it terminated Kristen K. Buck as EVP of Research and Development and Chief Medical Officer effective Aug. 3, 2026.
Legal action against Kuva Labs
- On July 31, Lisata commenced legal action against Kuva Labs and Kuva Acquisition Corp. for breach of merger agreement, according to the filing.
INVZ
•
